Mucosal Melanoma of the Head and Neck

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 15

PMID 22977596

Citations 3

Authors

Sayaka Kanetaka

Mamoru Tsukuda

Masahiro Takahashi

Masanori Komatsu

Tatsuo Niho

Choichi Horiuchi

Hideki Matsuda

Affiliations

Soon will be listed here.

Abstract

Mucosal melanoma of the head and neck (MMHN) is a rare malignant tumor associated with a poor prognosis. A retrospective study of case records of patients treated at our department between 1992 and 2010 was carried out. Thirteen patients were enrolled. The median age of the patients (3 males and 10 females) was 61 years (range 39-78). The median follow-up period was 48 months (range 10-115). Two common primary sites were the nasal cavity (8 cases) and sinonasal complex (5 cases). Ten patients (77%) received curative surgery. Chemotherapy was administered to 10 patients. In addition, lymphokine-activated killer (LAK) cell therapy was administered to 7 patients as adjunctive immunotherapy after the initial treatment course. The overall 5-year, cause-specific survival rate was 56%. Patients who received adjunctive LAK cell therapy had a survival rate of 67% at 5 years, while patients who did not receive adjunctive LAK cell treatment had a survival rate of 33%. MMHN is associated with a poor survival rate. The most common cause of death is distant metastasis. Surgery, radiotherapy and chemotherapy are common strategies for MMHN, but the control of metastasis is difficult. The use of immunotherapy remains uncommon for MMHN. However, from the viewpoint of a systemic disease, due to its high rate of metastases, immunotherapy using LAK cell treatment may contribute to the improvement of prognosis in patients with MMHN.

Citing Articles

Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis.

Li W, Yu Y, Wang H, Yan A, Jiang X BMC Cancer. 2015; 15:758.

PMID: 26490539 PMC: 4618517. DOI: 10.1186/s12885-015-1750-7.

Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma.

Meng X, Ao H, Huang W, Chen F, Sun X, Wang J BMC Cancer. 2014; 14:608.

PMID: 25149057 PMC: 4152585. DOI: 10.1186/1471-2407-14-608.

Solitary metastatic gallbladder malignant melanoma originated from the nasal cavity: A case report.

Furumoto K, Miyauchi Y, Ito D, Kitai T, Kogire M Int J Surg Case Rep. 2013; 4(11):965-8.

PMID: 24055919 PMC: 3825965. DOI: 10.1016/j.ijscr.2013.08.005.

References

Trotti A, Peters L . Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol. 1993; 9(3):246-50. View

Saito H, HOZAWA J, Yamagami M . [Statistical analysis of malignant melanoma of nasal cavity and paranasal sinuses in Japan]. Nihon Jibiinkoka Gakkai Kaiho. 1983; 86(2):139-43. View

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

Zenda S, Kawashima M, Nishio T, Kohno R, Nihei K, Onozawa M . Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys. 2010; 81(1):135-9. DOI: 10.1016/j.ijrobp.2010.04.071. View

Rosenberg S, Lotze M, Yang J, Topalian S, Chang A, Schwartzentruber D . Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993; 85(8):622-32. DOI: 10.1093/jnci/85.8.622. View

Tsukuda M, Mochimatsu I, Sakumoto M, Mikami Y, YUYAMA S, Yanoma S . The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes. Biotherapy. 1993; 6(3):167-74. DOI: 10.1007/BF01878077. View

Wada H, Nemoto K, Ogawa Y, Hareyama M, Yoshida H, Takamura A . A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys. 2004; 59(2):495-500. DOI: 10.1016/j.ijrobp.2003.11.013. View

Penel N, Mallet Y, Mirabel X, Ton Van J, Lefebvre J . Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 2006; 116(6):993-5. DOI: 10.1097/01.mlg.0000217236.06585.a9. View

Tsukuda M, Mochimatsu I, Sakumoto M, Furukawa S, YUYAMA S, Yanoma S . Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy. 1993; 6(2):155-61. DOI: 10.1007/BF01877429. View

10.

Atkins M, Kunkel L, Sznol M, Rosenberg S . High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000; 6 Suppl 1:S11-4. View

11.

Baba T, Sato-Matsushita M, Kanamoto A, Itoh A, Oyaizu N, Inoue Y . Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med. 2010; 8:84. PMC: 2949666. DOI: 10.1186/1479-5876-8-84. View

12.

Moreno M, Roberts D, Kupferman M, DeMonte F, El-Naggar A, Williams M . Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 2010; 116(9):2215-23. DOI: 10.1002/cncr.24976. View

13.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

14.

Omura K, Takemiya S, Shimada F, Shimada A, Ono I, Uchida M . [Malignant mucosal melanomas of the head and neck--collective review from six cancer hospitals]. Gan No Rinsho. 1986; 32(12):1511-8. View

15.

Mizoe J, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y . Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004; 60(2):358-64. DOI: 10.1016/j.ijrobp.2004.02.067. View

16.

Temam S, Mamelle G, Marandas P, Wibault P, Avril M, Janot F . Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2004; 103(2):313-9. DOI: 10.1002/cncr.20775. View

17.

Ballantyne A . Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970; 120(4):425-31. DOI: 10.1016/s0002-9610(70)80001-0. View

18.

Douglas C, Malik T, Swindell R, Lorrigan P, Slevin N, Homer J . Mucosal melanoma of the head and neck: radiotherapy or surgery?. J Otolaryngol Head Neck Surg. 2010; 39(4):385-92. View

19.

Ishihara K, Yamazaki N, Asano K . [Chemotherapy of malignant melanoma]. Gan To Kagaku Ryoho. 1993; 20(10):1287-92. View

20.

Gavriel H, McArthur G, Sizeland A, Henderson M . Review: mucosal melanoma of the head and neck. Melanoma Res. 2011; 21(4):257-66. DOI: 10.1097/CMR.0b013e3283470ffd. View